Dihexa

ID: dihexa

Aliases: N-hexanoic-Tyr-Ile-(6) aminohexanoic amide, angiotensin IV analog, HGF/c-Met small peptide-like mimetic

Type: compound

Route/form: no approved human route; preclinical work includes oral/systemic exposure

Status: research

Evidence level: preclinical

Best data tier: direct preclinical; adjacent human controlled/review + adjacent early human

Support scope: human, non-human/mechanistic, review/regulatory

Source types: early_human, preclinical, review, systematic_review

Linked sources: 4

Broad outcomes: Brain / mood / sleep

Reading note: These are curation notes anchored to linked sources, not a clinical recommendation or protocol.

Targets / mechanism

• HGF/c-Met pathway potentiation
• synaptogenesis
• angiotensin IV-derived cognitive pathway

Optimization domains

• cognition
• Alzheimers
• synaptogenesis
• neuroprotection
• CNS

Research basis

• Preclinical work reports Dihexa/HGF-c-Met pathway activity and cognitive/synaptogenic effects in dementia models.
• It belongs in the graph because nootropic communities often discuss it as unusually potent despite sparse human data.

Limits, risks, and missing evidence

• No approved human use or mature controlled human efficacy package was identified for Dihexa itself.
• HGF/c-Met pathway activation raises theoretical cancer, angiogenesis, and aberrant-growth concerns that are not resolved by rodent cognition studies.

Risk flags

• preclinical only
• CNS
• HGF cMet growth pathway
• neoplasm concern
• unapproved context

Linked papers, labels, and reviews

1. The procognitive and synaptogenic effects of angiotensin IV-derived peptides are dependent on activation of the hepatocyte growth factor/c-Met system
   preclinical / pubmed_dihexa_hgf_met_2014
   Key Dihexa mechanism paper linking HGF/c-Met modulation, synaptogenesis, and cognition models.
2. The role of HGF/c-Met signaling in cognitive enhancement by Dihexa
   review / pubmed_dihexa_hepatocyte_growth_factor_review_2015
   Mechanistic review of Dihexa and HGF/c-Met cognitive-enhancement rationale.
3. Cognitive benefits of Angiotensin IV and Angiotensin-(1-7): a systematic review of experimental studies
   systematic_review / pmc_angiotensin_iv_cognition_review_2022
   Experimental-study systematic review that discusses Dihexa as an AngIV-related procognitive compound.
4. Safety, tolerability, pharmacokinetics, and pharmacodynamics of fosgonimeton in healthy volunteers and subjects with Alzheimer's disease
   early_human / pubmed_fosgonimeton_phase1_2022
   Phase 1 HGF/MET positive-modulator context; fosgonimeton is related pathway context, not Dihexa itself.